New drug combo aims to stop stomach Cancer's return after surgery
NCT ID NCT06761846
Summary
This study is testing whether adding a drug called sintilimab to standard chemotherapy helps prevent cancer from coming back after surgery for stage III stomach or upper stomach cancer. About 70 people who have had surgery will receive the drug combination for up to 16 treatment cycles. Researchers will track how long participants remain cancer-free and monitor their safety and quality of life for several years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.